Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 2/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30127086 | 0.87 | HSD17B10 (0.55) | VCAM1HSD17B10LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL2816576 | 0.87 | HSD17B10 (0.55) | VCAM1HSD17B10LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL30648694 | 0.80 | ALDH1A1 (0.47) | VCAM1HSD17B10LMNAALDH1A1KDM4E | |
| SCHEMBL7880816 | 0.80 | ALDH1A1 (0.47) | VCAM1HSD17B10LMNAALDH1A1HPGD | |
| SCHEMBL1817832 | 0.80 | ALDH1A1 (0.47) | VCAM1HSD17B10LMNAALDH1A1KDM4E | |
| SCHEMBL8819027 | 0.80 | ALDH1A1 (0.58) | VCAM1HSD17B10LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL31156760 | 0.80 | ALDH1A1 (0.51) | VCAM1HSD17B10LMNAALDH1A1HPGD | |
| SCHEMBL18041455 | 0.80 | ALDH1A1 (0.51) | VCAM1HSD17B10LMNAALDH1A1HPGD | |
| SCHEMBL4612729 | 0.80 | VCAM1 (0.54) | VCAM1LMNASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL3999119 | 0.80 | ALDH1A1 (0.51) | VCAM1SMN1; SMN2ALDH1A1HPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1863774-B | Compounds and compositions as protein kinase inhibitors | IRM LLC | 2010-12-15 | — | — | CN | disclosed |
| US-20100249123-A1 | NOVEL BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE | ADDEX PHARMA SA (CH) | 2010-09-30 | — | — | US | disclosed |
| EP-2097374-B1 | 5-ALKYLOXY-INDOLIN-2-ONE DERIVATIVES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPY AS SELECTIVE LIGANDS OF V2 VASOPRESSIN RECEPTORS | SANOFI AVENTIS (FR) | 2010-06-09 | — | — | EP | disclosed |
| CN-101679215-A | New benzamide derivatives as the follicle stimulating hormone conditioning agent | ADDEX PHARMA SA | 2010-03-24 | — | — | CN | disclosed |
| US-20100069384-A1 | 5-ALKYLOXY-INDOLIN-2-ONE DERIVATIVES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPY | SANOFI-AVENTIS (FR) | 2010-03-18 | — | — | US | disclosed |
| EP-2134676-A2 | NOVEL BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE | Addex Pharma SA (CH) | 2009-12-23 | — | — | EP | disclosed |
| EP-2097374-A2 | 5-ALKYLOXY-INDOLIN-2-ONE DERIVATIVES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPY AS SELECTIVE LIGANDS OF V2 VASOPRESSIN RECEPTORS | Sanofi-Aventis (FR) | 2009-09-09 | — | — | EP | disclosed |
| US-7449582-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2008-11-11 | — | — | US | disclosed |
| US-7449582-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2008-11-11 | — | — | US | disclosed |
| WO-2008117175-A2 | NOVEL BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE | ADDEX PHARMA SA (CH) | 2008-10-02 | — | — | WO | disclosed |
| EP-1673343-A4 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-09-10 | — | — | EP | disclosed |
| WO-2008087278-A2 | 5-ALKYLOXY-INDOLIN-2-ONE DERIVATIVES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPY AS SELECTIVE LIGANDS OF V2 VASOPRESSIN RECEPTORS | SANOFI-AVENTIS (FR) | 2008-07-24 | — | — | WO | disclosed |
| CN-1863774-A | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2006-11-15 | — | — | CN | disclosed |
| WO-2006082452-A1 | OPTICALLY ACTIVE DIARYL ACETIC ACID DERIVATIVES AND PROCESS FOR THEIR PREPARATION | SANOFI-AVENTIS (FR) | 2006-08-10 | — | — | WO | disclosed |
| WO-2006079857-A1 | DIARYL ACETIC ACID DERIVATIVES AND THE PREPARATION THEREOF | SANOFI-AVENTIS (FR) | 2006-08-03 | — | — | WO | disclosed |
| WO-2006079857-A1 | DIARYL ACETIC ACID DERIVATIVES AND THE PREPARATION THEREOF | SANOFI-AVENTIS (FR) | 2006-08-03 | — | — | WO | disclosed |
| EP-1673343-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2006-06-28 | — | — | EP | disclosed |
| US-20050187230-A1 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2005-08-25 | — | — | US | disclosed |
| WO-2005034869-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2005-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249123-A1 | NOVEL BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE | FSHR, GNRHR, SHBG | VCAM1 2995/4885HSD17B10 3064/4885LMNA 1819/4885 |
| US-20050187230-A1 | Compounds and compositions as protein kinase inhibitors | FYN, LCK, SRC | VCAM1 2321/4885HSD17B10 4667/4885LMNA 4817/4885 |
| US-20100069384-A1 | 5-ALKYLOXY-INDOLIN-2-ONE DERIVATIVES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPY | AVPR2, AVPR1A, AVPR1B | VCAM1 365/4885HSD17B10 1915/4885LMNA 3010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.